Plasma-Derived Therapies Market

Purchase Option

$ 4400
$ 6600
$ 8900

Plasma-Derived Therapies Market Segmentation

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Plasma-Derived Therapies Market Introduction
2.1.Global Plasma-Derived Therapies Market - Taxonomy
2.2.Global Plasma-Derived Therapies Market - Definitions
2.2.1.By Product
2.2.2.By Disease / Medical Condition
2.2.3.By Region
3.Global Plasma-Derived Therapies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Plasma-Derived Therapies Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Plasma-Derived Therapies Market By Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Intravenous Immunoglobulin (IVIG)
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Clotting Factors Concentrates
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Protein C Concentrates
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Albumin
5.4.1.Albumin Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Factor VIII and IX
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Alpha-1 Antitrypsin (AAT)
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Hyperimmune Globulins
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Fibrinogen Concentrate
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Pooled Plasma Products
5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
5.10. Anti-Thymocyte Globulin (ATG)
5.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.10.3. Market Opportunity Analysis
5.11. Rho(D) Immune Globulin (RhIg)
5.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.11.3. Market Opportunity Analysis
5.12. Varicella-Zoster Immune Globulin (VZIG)
5.12.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.12.3. Market Opportunity Analysis
5.13. Tetanus Immune Globulin (TIG)
5.13.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.13.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.13.3. Market Opportunity Analysis
5.14. Others
5.14.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.14.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.14.3. Market Opportunity Analysis
6.Global Plasma-Derived Therapies Market By Disease / Medical Condition, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Immune Deficiencies
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Hemophilia and Bleeding Disorders
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Autoimmune Disorders
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Alpha-1 Antitrypsin (AAT) Deficiency
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Rabies Post-Exposure Prophylaxis
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Tetanus Prevention
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Cytomegalovirus Prevention in Transplant Recipients
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Varicella-Zoster Virus Prevention
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Hepatitis B Prevention
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Others
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
7.Global Plasma-Derived Therapies Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8.North America Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1.Intravenous Immunoglobulin (IVIG)
8.1.2.Clotting Factors Concentrates
8.1.3.Protein C Concentrates
8.1.4.Albumin
8.1.5.Factor VIII and IX
8.1.6.Alpha-1 Antitrypsin (AAT)
8.1.7.Hyperimmune Globulins
8.1.8.Fibrinogen Concentrate
8.1.9.Pooled Plasma Products
8.1.10.Anti-Thymocyte Globulin (ATG)
8.1.11.Rho(D) Immune Globulin (RhIg)
8.1.12.Varicella-Zoster Immune Globulin (VZIG)
8.1.13. Tetanus Immune Globulin (TIG)
8.1.14 Others
8.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1.Immune Deficiencies
8.2.2.Hemophilia and Bleeding Disorders
8.2.3.Autoimmune Disorders
8.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
8.2.5.Rabies Post-Exposure Prophylaxis
8.2.6.Tetanus Prevention
8.2.7.Cytomegalovirus Prevention in Transplant Recipients
8.2.8.Varicella-Zoster Virus Prevention
8.2.9.Hepatitis B Prevention
8.2.10.Others
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Intravenous Immunoglobulin (IVIG)
9.1.2.Clotting Factors Concentrates
9.1.3.Protein C Concentrates
9.1.4.Albumin
9.1.5.Factor VIII and IX
9.1.6.Alpha-1 Antitrypsin (AAT)
9.1.7.Hyperimmune Globulins
9.1.8.Fibrinogen Concentrate
9.1.9.Pooled Plasma Products
9.1.10.Anti-Thymocyte Globulin (ATG)
9.1.11.Rho(D) Immune Globulin (RhIg)
9.1.12.Varicella-Zoster Immune Globulin (VZIG)
9.1.13. Tetanus Immune Globulin (TIG)
9.1.14 Others
9.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Immune Deficiencies
9.2.2.Hemophilia and Bleeding Disorders
9.2.3.Autoimmune Disorders
9.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
9.2.5.Rabies Post-Exposure Prophylaxis
9.2.6.Tetanus Prevention
9.2.7.Cytomegalovirus Prevention in Transplant Recipients
9.2.8.Varicella-Zoster Virus Prevention
9.2.9.Hepatitis B Prevention
9.2.10.Others
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Intravenous Immunoglobulin (IVIG)
10.1.2.Clotting Factors Concentrates
10.1.3.Protein C Concentrates
10.1.4.Albumin
10.1.5.Factor VIII and IX
10.1.6.Alpha-1 Antitrypsin (AAT)
10.1.7.Hyperimmune Globulins
10.1.8.Fibrinogen Concentrate
10.1.9.Pooled Plasma Products
10.1.10.Anti-Thymocyte Globulin (ATG)
10.1.11.Rho(D) Immune Globulin (RhIg)
10.1.12.Varicella-Zoster Immune Globulin (VZIG)
10.1.13. Tetanus Immune Globulin (TIG)
10.1.14 Others
10.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Immune Deficiencies
10.2.2.Hemophilia and Bleeding Disorders
10.2.3.Autoimmune Disorders
10.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
10.2.5.Rabies Post-Exposure Prophylaxis
10.2.6.Tetanus Prevention
10.2.7.Cytomegalovirus Prevention in Transplant Recipients
10.2.8.Varicella-Zoster Virus Prevention
10.2.9.Hepatitis B Prevention
10.2.10.Others
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Latin America Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Intravenous Immunoglobulin (IVIG)
11.1.2.Clotting Factors Concentrates
11.1.3.Protein C Concentrates
11.1.4.Albumin
11.1.5.Factor VIII and IX
11.1.6.Alpha-1 Antitrypsin (AAT)
11.1.7.Hyperimmune Globulins
11.1.8.Fibrinogen Concentrate
11.1.9.Pooled Plasma Products
11.1.10.Anti-Thymocyte Globulin (ATG)
11.1.11.Rho(D) Immune Globulin (RhIg)
11.1.12.Varicella-Zoster Immune Globulin (VZIG)
11.1.13. Tetanus Immune Globulin (TIG)
11.1.14 Others
11.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Immune Deficiencies
11.2.2.Hemophilia and Bleeding Disorders
11.2.3.Autoimmune Disorders
11.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
11.2.5.Rabies Post-Exposure Prophylaxis
11.2.6.Tetanus Prevention
11.2.7.Cytomegalovirus Prevention in Transplant Recipients
11.2.8.Varicella-Zoster Virus Prevention
11.2.9.Hepatitis B Prevention
11.2.10.Others
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Brazil
11.3.2.Mexico
11.3.3.Rest of LA
12.Middle East and Africa Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Intravenous Immunoglobulin (IVIG)
12.1.2.Clotting Factors Concentrates
12.1.3.Protein C Concentrates
12.1.4.Albumin
12.1.5.Factor VIII and IX
12.1.6.Alpha-1 Antitrypsin (AAT)
12.1.7.Hyperimmune Globulins
12.1.8.Fibrinogen Concentrate
12.1.9.Pooled Plasma Products
12.1.10.Anti-Thymocyte Globulin (ATG)
12.1.11.Rho(D) Immune Globulin (RhIg)
12.1.12.Varicella-Zoster Immune Globulin (VZIG)
12.1.13. Tetanus Immune Globulin (TIG)
12.1.14 Others
12.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Immune Deficiencies
12.2.2.Hemophilia and Bleeding Disorders
12.2.3.Autoimmune Disorders
12.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
12.2.5.Rabies Post-Exposure Prophylaxis
12.2.6.Tetanus Prevention
12.2.7.Cytomegalovirus Prevention in Transplant Recipients
12.2.8.Varicella-Zoster Virus Prevention
12.2.9.Hepatitis B Prevention
12.2.10.Others
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.GCC Countries
12.3.2.South Africa
12.3.3.Rest of MEA
13. Competition Landscape
13.1. Market Player Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
13.2.1.Takeda Pharmaceutical Company
13.2.2.Grifols
13.2.3.CSL Behring
13.2.4.Octapharma
13.2.5.Bio Products Laboratory (BPL)
13.2.6.Kedrion Biopharma
13.2.7.Biotest
13.2.8.China Biologic Products
13.2.9.Kamada
13.2.10.LFB Biomedicaments
14. Research Methodology
15. Appendix and Abbreviations
• Takeda Pharmaceutical Company
• Grifols
• CSL Behring
• Octapharma
• Bio Products Laboratory (BPL)
• Kedrion Biopharma
• Biotest
• China Biologic Products
• Kamada
• LFB Biomedicaments

Adjacent Markets